A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)
Status:
Recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, crossover study comparing asthma
control post treatment in African American/Black and Caucasian/White children in both hyper
and hypo responsive HILD (Histamine Lontophoresis with Laser Doppler monitoring) phenotypes
with uncontrolled persistent allergic asthma using Levocetirizine (LTZ) vs placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Bridgette Jones Children's Mercy Hospital Kansas City